hello world
Provided Content: Content provided by Baystreet. The Globe and Mail was not involved, and material was not reviewed prior to publication.
Stocks in play: Eupraxia Pharmaceuticals Inc.
Announced additional positive clinical data from its RESOLVE Phase 1b/2a trial, which is evaluating the safety and efficacy of EP-104GI as a treatment for eosinophilic esophagitis. Eupraxia Pharmaceuticals Inc. shares T.EPRX are trading up $0.34 at $3.69.
